Pharmagest Interactive SA (0R9T.L)
| Previous close | 101.20 |
| Open | 102.80 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 102.60 - 103.40 |
| 52-week range | 102.60 - 103.40 |
| Volume | 844 |
| Avg. volume | N/A |
| Market cap | 1.513B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | 57.33 |
| EPS (TTM) | 1.80 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Pharmagest Interactive: Strategic partnership with Elsan
PRESS RELEASE Strategic partnership between ELSAN and Pharmagest Group to develop relations with private practitioners through PandaLab’s instant messaging app for medical professionals ELSAN, a leading private healthcare operator in France caring for 2 million patients each year at its 120 private clinics and hospitals, and Pharmagest Group, the majority shareholder of PandaLab, finalize a strategic partnership to optimize interactions and information flows between hospital and private practice office-based healthcare professionals. PandaLab makes its instant messaging app, PandaLab Pro, available to ELSAN’s 120 private clinics and hospitals.ELSAN acquires a minority stake in PandaLab. Paris and Villers-lès-Nancy, 19 April 2021 - 07:30 a.m. (CET) - After signing a partnership agreement in January 2020 with PandaLab for its secure instant messaging app for hospital and private practice office-based healthcare professionals, ELSAN, a leading private healthcare operator in France, entered into a strategic partnership with the Health and Social Care Facilities Solutions (HSCFS) Division of Pharmagest Group (Euronext Paris™ - Compartment B - ISIN: FR 0012882389), managed by its subsidiary MALTA INFORMATIQUE, to develop relations with private practice office-based healthcare professionals through the health sector instant messaging app developed by PandaLab, a Pharmagest Group subsidiary. To solidify this partnership, ELSAN acquired a minority stake in the start-up, joining its founders and Pharmagest Group, the reference shareholder, whose majority stake remains unchanged (at 56.27% of PandaLab’s capital since April 2020). This strategic partnership will accelerate PandaLab’s deployment in France by equipping ELSAN network of private clinics and hospitals with its PandaLab Pro solution. It will also contribute the goal of the HSCFS Division, operating under the direction of MALTA INFORMATIQUE, a Pharmagest Group subsidiary, of establishing PandaLab Pro as a key tool for communications between all healthcare professionals, whether in private practice, social care establishments or hospitals in France and in Europe. PandaLab Pro, an intuitive, easy-to-use, multifunctional and secure tool for sharing health data with private practice office-based physicians, whose adoption has been accelerated by the health crisis In the context of the health crisis where healthcare professionals need to be informed and communicate quickly, the PandaLab Pro app has been deployed in half of ELSAN's clinics and hospitals with a volume of nearly 750,000 messages in less than one year. The implementation of this intuitive and easy-to-use instant messaging app from a computer or smart phone secures and facilitates internal communications not only between healthcare professionals and other staff but also with private practice physicians through a specific module developed conjointly by PandaLab and ELSAN. In this way, establishments using PandaLab Pro facilitate the work of private practice healthcare professionals by offering them a seamless and secure communications tool. Nearly 800 private practice healthcare professionals have already been invited to join the groups formed within ELSAN’s private hospitals relating to their activity. This tool makes it possible to enter directly into contact with the relevant department or medical team, obtain an opinion by the establishment’s practitioners, transfer an x-ray, rapidly obtain a response or be directed to the right correspondent. PandaLab Pro is thus for example used between the medical services of ELSAN’s private hospitals and senior homes, between hospital pharmacists and independent pharmacies or by chronic wound care units to communicate with domiciliary nurses. This tool adapts to each communications need with ambitious goals: improving the efficiency of care, improving the quality of the interaction, reducing time required to obtain information. Simon LEVY, Executive Vice President for Strategy and Development at ELSAN commented: “Our investment in PandaLab will accelerate its deployment by developing communications between hospital and private practice healthcare professionals to improve coordination in providing care to the two million patients we receive each year." Grégoire de ROTALIER, Deputy Managing Director of Pharmagest Group and Head of Pharmagest Group's Health and Social Care Facilities Solutions Division added: “PandaLab’s integration into all our software applications (pharmacies, senior homes, hospitals-at-home, in-home nursing services, hospitals, health centres and private practice physicians) combined with ELSAN’s extensive regional network of private clinics and hospitals will help establish PandaLab as a major tool for communications between hospital and private practice healthcare professionals." Christelle MASSON, Chief Executive Officer of PandaLab concluded: “We are very proud that ELSAN has decided to join our shareholder base alongside Pharmagest Group. This will allow us to accelerate the rollout of PandaLab Pro in France and continue to demonstrate the utility of this application for the coordination of the patient care pathway”. About ELSANFrance’s foremost private healthcare provider, ELSAN has a strong presence throughout the country meeting patient needs in all areas. ELSAN has 25,000 employees and 6,500 privately operating practitioners at 120 clinics and hospitals in all parts of France, providing treatment and services to more than two million patients a year. Our mission: delivering innovative, high-quality care with a human touch. www.elsan.care About PandaLab - www.pandalab.frPandaLab, the developer of e-Health software solution, PandaLab Pro, is a French start-up founded by Dr. Aurélien LAMBERT, a medical oncologist. The application for healthcare professionals and medical secretaries has more than 7,500 paying users throughout France. PandaLab is a cutting edge provider of e-Health solutions designed to coordinate and streamline the entire patient care pathway. PandaLab has been a Pharmagest Group subsidiary since 2020. About MALTA INFORMATIQUE and the Health and Social Care Facilities Solutions Division of Pharmagest Group MALTA INFORMATIQUE, a wholly-owned subsidiary of Pharmagest Group, is an independent software vendor specialised in applications for senior homes and day care facilities for the elderly, a fast-growing sector in which it has a 28 % market share. Its TITAN application is the only solution on the market with the ability to cover the entire medication pathway for senior homes. At 31 December 2020, MALTA INFORMATIQUE equipped 2,220 senior homes.MALTA INFORMATIQUE is the operating company responsible for spearheading Pharmagest Group's Health and Social Care Facilities Solutions Division (189 employees; 2019 sales: €26.19 million; installed base: more than 3,500 establishments). With its subsidiaries DICSIT INFORMATIQUE, AXIGATE, ICT, PANDALAB and MALTA BELGIUM, this Division also operates across a number of sectors including e-Health, hospitals at home, home-based nursing services, hospitals and health centres and facilities housing multiple disciplines. About Pharmagest Group: www.pharmagest.com - Follow Pharmagest on Twitter: @Pharmagest, LinkedIn and FacebookWith more than 1,100 employees acting as “Citizens in the Service of Health and Well-Being”, Pharmagest Group is the leading provider of IT solutions for the healthcare sector in Europe through innovative solutions and services for healthcare professionals guaranteeing the efficiency of the healthcare system and improving the patient care pathway.As a key contributor to the quality of healthcare and coordination between office-based private practice and hospitals, Pharmagest Group is present in France, Italy, Belgium, Luxembourg and the United Kingdom where it is developing the leading healthcare platform and a single ecosystem for France and Europe bringing the best of technology to the service of people. Listed on Euronext Paris™ - Compartment BIndices: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-TradableIncluded under the European Rising Tech label Eligible for the “long-only” Deferred Settlement Service (“Service à Règlement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME)ISIN: FR 0012882389 – Reuters: PHA.PA – Bloomberg: - PMGI FP CONTACTS ELSANPress Contact: Pénélope de FOUQUIERESTel.: +33 (0)6 31 34 81 24 – fouquieres@elsan.care MALTA INFORMATIQUEChairman and Head of Pharmagest Group's Health and Social Care Facilities Solutions Division. Grégoire de ROTALIERTel.: +33 (0)5 57 35 19 25 – gregoire.derotalier@malta-informatique.fr PANDALABChief Executive Officer: Christelle MASSONTel.: +33 (0)1 84 25 79 21 – christelle.masson@pandalab.fr PHARMAGEST GROUPPress Contact: Isabelle APRILEMobile: +33 (0)6 17 38 61 78 – i.aprile@finextenso.fr Attachment PHARMAGEST_PRESSRELEASE_20210419_STRATEGIC PARTNERSHIP WITH ELSAN
- Globe Newswire
PHARMAGEST GROUP strengthens its network in Paris Regions by acquiring ADI
Villers-lès-Nancy, March 1, 2021- 6:00 p.m. (CET) PRESS RELEASE PHARMAGEST GROUP STRENGTHENS ITS DISTRIBUTION NETWORK IN THE GREATER PARIS REGION BY ACQUIRING ITS HISTORIC DISTRIBUTOR, ADI Pharmagest Group becomes the sole shareholder of ADI (Applications et Développements Informatiques), in which it previously held 50% of the capital.This acquisition enables the Group to control its historic distributor in Ile-de-France for more than 30 years.Highlighting Pharmagest Group’s commitment to strengthen its distribution network in the greater Paris region. *** Pharmagest Group (Euronext Paris – Compartment B - ISIN : FR 0012882389), the leading provider of IT solutions for the healthcare sector in Europe, today announces having acquired the 50% stake held by Marc ABITBOL, founder of ADI, the distribution partner of Pharmagest Group’s solutions in Ile-de-France for more than 30 years. Pharmagest Group now has a homogeneous network of regional agencies adapted to its distribution model and fully integrated within metropolitan France and the French West Indies. ADI was the last structure in metropolitan France not fully integrated at the level of the capital, whereas ADI’s revenue was already fully consolidated by the Group in terms of revenue since 2000 (ADI 2020 revenue: €5.8 million). Until now, pharmacists in Ile-de-France had access to only a part of the PHARMAGEST catalogue of products and services. Henceforth, the Group will be able to support the entire ecosystem for the business lines it develops. By deploying Pharmagest Group’s operating and commercial processes across the ADI network, Management expects to generate strong growth in business and earnings in Ile-de-France over the next three years. Thierry CHAPUSOT, Chairman of the Board of Directors of Pharmagest Group, commented: “Through this transaction, we have completed fully integrating our distribution network which will allow us to offer existing and potential customers in the greater Paris region the complete range of solutions and services developed by the Group. This represents a logical development in the Group’s evolution in this region which accounts for 18% of French pharmacies. As a result, we now have a modern local network in Ile-de-France that we intend to optimize to accelerate our development and increase our market share. By leveraging the commitment of our teams and those of ADI as well as the Group’s operating in commercial methods underpinning its success, we will expect to see growth in revenue and earnings in this region.”Financial calendar: 2020 Annual Results: 26 March 2021 after the close of trading.Information meeting on 2020 Annual Results: 29 March 2021 at 2:30 p.m. About Pharmagest Group: With more than 1,100 employees acting as “Citizens in the Service of Health and Well-Being”, Pharmagest Group is the leading provider of IT solutions for the healthcare sector in Europe through innovative solutions and services for healthcare professionals guaranteeing the efficiency of the healthcare system and improving the patient care pathway. As a key contributor to the quality of healthcare and coordination between office-based private practice and hospitals, Pharmagest Group is present in France, Italy, Belgium, Luxembourg and the United Kingdom where it is developing the leading healthcare platform and a single ecosystem for France and Europe bringing the best of technology to the service of people. Listed on Euronext Paris™ - Compartment BIndexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2019 - CAC® SMALL and CAC® All-TradableIncluded under the European Rising Tech label. Eligible for the “long-only” Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).ISIN: FR 0012882389 – Reuters: PHA.PA – Bloomberg: - PMGI FP For all the latest news go to www.pharmagest.com Follow Pharmagest on Twitter: @Pharmagest, LinkedIn and Facebook CONTACTS Analyst and Investor Relations: Chief Administrative and Financial Officer: Jean-Yves SAMSONTel. +33 (0)3 83 15 90 67 - jean-yves.samson@lacooperativewelcoop.com Media Relations: FIN’EXTENSO - Isabelle APRILETel. +33 (0)1 39 97 61 22 - i.aprile@finextenso.fr Attachment PHARMAGEST_PRESSRELEASE_20210301_ADI Acquisition_en_US
- Globe Newswire
Pharmagest Interactive: 2020 annual sales: €171.75 million, +8.32%
Villers-lès-Nancy, 4 February 2021 - 6:00 p.m. (CET) PRESS RELEASE 2020 annual sales: €171.75 million, +8.32% A strong rebound in sales in H2 2020: €93.82 million, +14.85%. Like-for-like sales (excluding the disposal of INTECUM and the acquisitions of MALTA BELGIUM, ICT, SVEMU, I-MEDS, PANDALAB, ASCA INFORMATIQUE): €84.37 million, +3.28%. The Group’s external growth strategy remains on track: Positive impact of acquisitions (MALTA BELGIUM, ICT, SVEMU, I-MEDS, PANDALAB, ASCA INFORMATIQUE): +8.05% with annual sales of €12.77 million. The Group confirms the strength of its business model combining recurrent revenue with a diverse portfolio of health-related businesses: Like-for-like annual sales remain steady at €158.98 million (+0.49%). 2021 outlook: continuing the Group strategy of technological transformation to increase patient care pathway efficiencies across the office-based private practice and hospital spectrum. In €m 2020*2019ChangeQ139.0038.15 +2.23%Q238.9338.73+0.52%H177.9376.88+1.37%Q344.3435.28 +25.70%Q449.4846.41+6.61%H293.8281.69+14.85%Annual revenue171.75158.57+8.32%** * unaudited** +0.49% like-for-like, excluding the disposal of INTECUM and excluding acquisitions of MALTA BELGIUM, ICT, SVEMU, I-MEDS, PANDALAB, ASCA INFORMATIQUE. ******** 2020 highlights ·The Pharmacy - Europe Solutions Division had annual revenue of €127.31 million, up 5.05% from 2019. Like-for-like (excluding the disposal of INTECUM and the acquisitions of SVEMU and ASCA INFORMATIQUE), annual revenue remained stable (-0.44% to €120.30 million). In France, by implementing operating procedures early on designed to strengthen ties with customers, the Group was able to satisfy the strong recovery in demand starting in June (installations and pharmacies postponed, growth in orders fuelled by the launch of new offerings) and adapt to the announcement of a 2nd phase of lockdown. These measures helped reduce the impact of the epidemic and maintain the level of annual sales in relation to 2019: +5.92%. The second half was also boosted by ASCA INFORMATIQUE’s integration on 1 July which contributed €6.6 million in sales. In Italy, the business mix combining wholesalers - distributors and pharmacies helped limit the impact of the health crisis. Like-for-like, the Pharmacy Italy Business Unit declined marginally by 0.42% to €7.14 million. SVEMU’s integration which contributed €602,000 in sales ensured the growth of this Business Unit: +5.30% for 2020.In Belgium, which was impacted by very stringent restrictions linked to the level of the lockdown measures, sales decreased 20.63% to €3 million and represented only 2.37% of the Division’s total sales in 2020. This Division accounted for 74.12% of Pharmagest Group's revenue for 2020. ·The Health and Social Care Facilities Solutions Division registered sustained growth in the period: +34.27% with annual sales of €26.19 million. This significant growth confirms the efficiency of the strategy for European development initiated by the Division in a context where the health crisis has highlighted the vital need for breaking down barriers between office-based private practices and hospitals: expansion in Belgium with the acquisition of CARE SOLUTIONS and creation of its subsidiary MALTA BELGIUM, diversification of activities with the acquisitions of ICT and PANDALAB. Like-for-like, the Division grew 6.66%.Whereas the senior homes and hospital-at-home sectors experienced a relatively difficult period in the second half linked to the development of the epidemic, new contracts signed by AXIGATE with the Gisors and Andelys Hospital Centres of the Eure-Seine Regional Hospital Network and the Arles Hospital Centre contributed to growth in the amount of 5.10% (30% of orders remaining to be executed in 2021). This Division accounted for 15.25% of Pharmagest Group's revenue for 2020. ·Annual revenue for the e-Health Solutions Division remained steady: €16.44 million (+1.97%). This Division experienced mixed performances in the second half: following a modest recovery, the Digital Communications business registered renewed momentum at year end which was not however sufficient to offset the business slowdown for connected readers.The integration of I-MEDS in Germany in Q1 2020 furthermore supported the development of the Medication Compliance activity and contributed €374,000. Like-for-like, annual revenue remained steady (-0.36% to €16.06 million). This Division accounted for 9.57% of Pharmagest Group's revenue for 2020. ·The Fintech Division had revenue of €1.81 million at 31 December 2020, a 3.75% increase in relation to 2019. In a market situation impacted by weaker investments in the first half, this Division is back on track with a significant rebound in the second half: €1.13 million in sales, up 15.64%. This Division accounted for 1.06% of Pharmagest Group's revenue for 2020. Significant subsequent events 30% of NANCEO shares (Fintech Division) sold to operational members. Launched in Q2 2015, NANCEO's (Fintech Division) aim is to become a genuine financing solutions marketplace for the sale of equipment and services. The Leasa by Nancéo platform is today recognized by top-tier partners as a contributor to an increasingly important service offering and is continuing to offer proposals with best financial terms. The purpose of this share sale is to promote the participation of operational staff in NANCEO’s success and incentivize their ongoing support in developing the activity and business volume both in France and international markets. Outlook 2021 FY 2020 was impacted by the COVID-19 epidemic. In this unprecedented context, Pharmagest Group demonstrated the resilience of its business model and the strength of its strategy both by combining solid growth in sales with the completion of strategic acquisitions. On that basis, the Group is expecting excellent results for FY 2020. And while the epidemic is expected to continue in 2021 with recurrent episodes in the years ahead, it is very likely that digital healthcare solutions will be the focus of massive investments by European governments. In this context, as a major Health IT player and innovator, Pharmagest Group is continuing roll out its new solutions to support and coordinate all business lines within the health ecosystem and use technology to optimize the patient care pathway across the office-based private practice and hospital segments. It will also continue to pursue significant business growth, while confirming its commitment to pursue in 2021 targeted new acquisitions in France and in Europe. In September 2020, Pharmagest Group confirmed its ambitions as a signatory of the e-Health charter ("Engagé pour la e-Santé”), an initiative spearheaded by the French Ministerial Delegation for Digital Health. Pharmagest Group intends to share its values and join forces with the 320 industrial signatories to successfully complete several digital projects essential for the modernization of the healthcare system and improvement of patient care in the health and social care sectors. Financial calendar: 2020 Annual Results: 26 March 2021 after the close of trading.Information meeting on 2020 Annual Results: 29 March 2021, 2:30 p.m. - Paris. About Pharmagest Group: With more than 1,100 employees acting as “Citizens in the Service of Health and Well-Being”, Pharmagest Group is the leading provider of IT solutions for the healthcare sector in Europe through innovative solutions and services for healthcare professionals guaranteeing the efficiency of the healthcare system and improving the patient care pathway. As a key contributor to the quality of healthcare and coordination between office-based private practice and hospitals, Pharmagest Group is present in France, Italy, Belgium, Luxembourg and the United Kingdom where it is developing the leading healthcare platform and a single ecosystem for France and Europe bringing the best of technology to the service of people. Listed on Euronext Paris™ - Compartment BIndexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2019 - CAC® SMALL and CAC® All-Tradable Included under the European Rising Tech label Eligible for the “long-only” Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME)ISIN: FR 0012882389 – Reuters: PHA.PA – Bloomberg: - PMGI FP For all the latest news go to www.pharmagest.com Follow Pharmagest on Twitter: @Pharmagest, LinkedIn and Facebook CONTACTS Analyst and Investor Relations: Chief Administrative and Financial Officer : Jean-Yves SAMSONTel. +33 (0)3 83 15 90 67 - jean-yves.samson@lacooperativewelcoop.com Media Relations: FIN’EXTENSO - Isabelle APRILE Tel. +33 (0)1 39 97 61 22 - i.aprile@finextenso.fr Attachment PHARMAGEST_PRESSRELEASE_20210204_2020 REVENUE
